[Unrelated peripheral blood stem cell transplantation for a patient with acute myeloid leukemia].
OBJECTIVE
To carry out unrelated donor peripheral blood stem cell transplantation for treatment of hematological malignancies, and to observe the persistent hematopoietic reconstitution and transplantation related complications.


METHODS
A 11-year-old boy with acute myeloid leukemia, who was in second CR, received peripheral blood stem cell transplantation from a unrelated healthy adult donor. The conditioning regimen consisted of FTBI (8Gy), cyclophosphamide (120 mg/kg) and Vp16 (30 mg/kg). The patient received 8. 3 x 10(8) mononuclear cells/kg, 1.079 x 10(8) CD34+ cells/kg and 1. 09 x 10(6) CFU-GM/kg. CsA and MTX were given for prophylaxis of aGVHD.


RESULTS
Engraftment with allogeneic peripheral blood stem cells was rapid, ANC reached 1. 30 x 10(9)/L on day 10 post-transplantation, DNA D1S80 showed engraftment on day 23, and the blood type(AB) changed into the donor's (A) on day 120. The patient developed mild aGVHD (I degrees) on day 11 and mild cGVHD on day 143, which were controlled by methylprednisolone and prednisone, respectively. Ten months after transplantation, the patient's blood counts were normal.


CONCLUSIONS
Unrelated donor peripheral blood stem cell can maintain persistent hematopoiesis.
Xie
Y
Y
Huashan Hospital, Shanghai Medical University, Shanghai 200040.
Xie
Y
Y
Jiang
Q
Q
D000328:Adult; D001854:Bone Marrow Cells / Q000166:cytology; D002648:Child; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000209:etiology; D006410:Hematopoiesis; D006801:Humans; D007951:Leukemia, Myeloid / Q000276:immunology / Q000473:pathology / Q000601:surgery*; D008297:Male; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects; D014184:Transplantation, Homologous